Revenue
$14.92B
Gross Margin
+84.5%
Operating Margin
+24.3%
Net Margin
+29.6%
Income statement waterfall for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
Net income: $4.42B
Margin breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $14.92B | $14.92B |
| Cost of Revenue | −$2.31B | $12.61B |
| Gross Profit | $12.61B | $12.61B |
| Operating Expenses | −$8.98B | $3.63B |
| Operating Income | $3.63B | $3.63B |
| Other Income / Expense | $1.53B | $5.16B |
| Pre-tax Income | $5.16B | $5.16B |
| Income Tax | −$733.50M | $4.42B |
| Net Income | $4.42B | $4.42B |
- Revenue$14.92B
- Cost of Revenue−$2.31B
- Gross Profit$12.61B
- Operating Expenses−$8.98B
- Operating Income$3.63B
- Other Income / Expense$1.53B
- Pre-tax Income$5.16B
- Income Tax−$733.50M
- Net Income$4.42B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement